US6207646B1
(en)
*
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
BRPI0413558A
(pt)
|
2003-08-12 |
2006-10-17 |
3M Innovative Properties Co |
compostos contendo imidazo substituìdo por hidroxilamina
|
KR101106812B1
(ko)
|
2003-08-27 |
2012-01-19 |
쓰리엠 이노베이티브 프로퍼티즈 컴파니 |
아릴옥시 및 아릴알킬렌옥시 치환된 이미다조퀴놀린
|
WO2005023190A2
(en)
|
2003-09-05 |
2005-03-17 |
3M Innovative Properties Company |
Treatment for cd5+ b cell lymphoma
|
US7544697B2
(en)
|
2003-10-03 |
2009-06-09 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and analogs thereof
|
CA2540541C
(en)
|
2003-10-03 |
2012-03-27 |
3M Innovative Properties Company |
Alkoxy substituted imidazoquinolines
|
CN1906192A
(zh)
|
2003-11-14 |
2007-01-31 |
3M创新有限公司 |
羟胺取代的咪唑环化合物
|
JP2007511527A
(ja)
|
2003-11-14 |
2007-05-10 |
スリーエム イノベイティブ プロパティズ カンパニー |
オキシム置換イミダゾ環化合物
|
JP4891088B2
(ja)
|
2003-11-25 |
2012-03-07 |
スリーエム イノベイティブ プロパティズ カンパニー |
置換されたイミダゾ環系および方法
|
FR2863890B1
(fr)
*
|
2003-12-19 |
2006-03-24 |
Aventis Pasteur |
Composition immunostimulante
|
EP1701955A1
(en)
|
2003-12-29 |
2006-09-20 |
3M Innovative Properties Company |
Arylalkenyl and arylalkynyl substituted imidazoquinolines
|
JP2007517055A
(ja)
*
|
2003-12-30 |
2007-06-28 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫応答の増強
|
WO2005066169A2
(en)
|
2003-12-30 |
2005-07-21 |
3M Innovative Properties Company |
Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
|
WO2005094531A2
(en)
|
2004-03-24 |
2005-10-13 |
3M Innovative Properties Company |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
JP2007535924A
(ja)
|
2004-05-07 |
2007-12-13 |
− グスタフ ユングレン、ハンス |
ワクチン用アジュバントとしてのフラジェリンの使用
|
US8017779B2
(en)
|
2004-06-15 |
2011-09-13 |
3M Innovative Properties Company |
Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
US7915281B2
(en)
|
2004-06-18 |
2011-03-29 |
3M Innovative Properties Company |
Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
|
WO2006038923A2
(en)
|
2004-06-18 |
2006-04-13 |
3M Innovative Properties Company |
Aryl substituted imidazonaphthyridines
|
WO2006009826A1
(en)
|
2004-06-18 |
2006-01-26 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
|
AU2005322898B2
(en)
|
2004-12-30 |
2011-11-24 |
3M Innovative Properties Company |
Chiral fused (1,2)imidazo(4,5-c) ring compounds
|
ES2392648T3
(es)
|
2004-12-30 |
2012-12-12 |
3M Innovative Properties Company |
Compuestos quirales sustituidos que contienen un núcleo 1,2-imidazo-4,5-c condensado
|
EP1844201B1
(en)
|
2005-02-04 |
2016-08-24 |
3M Innovative Properties Company |
Aqueous gel formulations containing immune response modifiers
|
JP2008530113A
(ja)
|
2005-02-11 |
2008-08-07 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
オキシムおよびヒドロキシラミン置換イミダゾ[4,5−c]環化合物および方法
|
JP2008538550A
(ja)
|
2005-04-01 |
2008-10-30 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
ウイルス感染および腫瘍性疾患を処置するためのサイトカイン生合成の調節因子としての1−置換ピラゾロ(3,4−c)環状化合物
|
JP2008535832A
(ja)
|
2005-04-01 |
2008-09-04 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
ピラゾロピリジン−1,4−ジアミン、およびそのアナログ
|
EP2614709A1
(en)
|
2005-07-18 |
2013-07-17 |
Novartis AG |
Small animal model for HCV replication
|
CA2623764A1
(en)
*
|
2005-09-27 |
2007-04-05 |
Coley Pharmaceutical Gmbh |
Modulation of tlr-mediated immune responses using adaptor oligonucleotides
|
ES2370040T3
(es)
|
2005-10-07 |
2011-12-12 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. |
Vacuna de metaloproteinasa 11 de la matriz.
|
CA2523032A1
(en)
|
2005-10-07 |
2007-04-07 |
Immunovaccine Technologies Inc. |
Vaccines for cancer therapy
|
PT2347775T
(pt)
|
2005-12-13 |
2020-07-14 |
The President And Fellows Of Harvard College |
Estruturas em andaime para transplante celular
|
AU2007220988B2
(en)
*
|
2006-02-28 |
2010-06-03 |
Vaxart, Inc |
Chimeric adenoviral vectors
|
CA2646539A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Imidazoquinoxaline compounds as immunomodulators
|
JP5427027B2
(ja)
*
|
2006-05-03 |
2014-02-26 |
ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド,ア・ボディー・コーポレイト |
Cd40アゴニスト抗体/i型インターフェロン相乗性アジュバントの結合体、それを含む複合体、および細胞性免疫を強化する治療としてのその使用
|
MX2008013993A
(es)
|
2006-05-03 |
2009-05-11 |
Univ Colorado |
Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular.
|
US7906506B2
(en)
|
2006-07-12 |
2011-03-15 |
3M Innovative Properties Company |
Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
|
AU2007276219B2
(en)
|
2006-07-18 |
2013-10-03 |
Glaxosmithkline Biologicals S.A. |
Vaccines for malaria
|
GB0617387D0
(en)
*
|
2006-09-04 |
2006-10-11 |
Glaxo Group Ltd |
Synthetic gene
|
EP2137210B1
(en)
|
2007-03-02 |
2016-10-19 |
GlaxoSmithKline Biologicals SA |
Novel method and compositions
|
DE102007044093A1
(de)
*
|
2007-09-14 |
2009-03-19 |
Phenion Gmbh & Co. Kg |
Nukleinsäurehaltige kosmetische und/oder pharmazeutische Zubereitungen zur Induktion antimikrobieller Peptide in epithelialen Deckgeweben
|
CN101827613A
(zh)
|
2007-09-27 |
2010-09-08 |
免疫疫苗技术有限公司 |
在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
|
WO2009059328A2
(en)
*
|
2007-11-02 |
2009-05-07 |
The Johns Hopkins University |
Multi- component l2 vaccine for prevention of human papillomavirus infection
|
KR100900837B1
(ko)
*
|
2007-12-07 |
2009-06-04 |
(주)두비엘 |
리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물
|
JP5690143B2
(ja)
|
2008-02-13 |
2015-03-25 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
持続的細胞プログラミング装置
|
JP5190628B2
(ja)
*
|
2008-03-31 |
2013-04-24 |
一般財団法人阪大微生物病研究会 |
混合免疫賦活剤を含む新規ワクチン
|
US8410258B2
(en)
|
2008-05-21 |
2013-04-02 |
Infections Disease Research Institute |
Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
|
EP2300051B1
(en)
*
|
2008-05-21 |
2014-11-12 |
Infectious Disease Research Institute |
Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
|
EP2296696B1
(en)
|
2008-06-05 |
2014-08-27 |
ImmunoVaccine Technologies Inc. |
Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
|
US20100160368A1
(en)
|
2008-08-18 |
2010-06-24 |
Gregory Jefferson J |
Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
|
EP2331119A4
(en)
*
|
2008-09-24 |
2012-05-30 |
Univ Johns Hopkins |
MALARIA VACCINE
|
WO2010063865A1
(es)
|
2008-12-03 |
2010-06-10 |
Proyecto De Biomedicina Cima, S.L. |
Uso de modulinas solubles en fenol para el desarrollo de vacunas
|
US8552165B2
(en)
*
|
2008-12-09 |
2013-10-08 |
Heather Davis |
Immunostimulatory oligonucleotides
|
PL2376107T3
(pl)
|
2008-12-09 |
2014-09-30 |
Coley Pharm Group Inc |
Oligonukleotydy immunostymulujące
|
RU2585961C9
(ru)
|
2009-05-22 |
2016-12-27 |
Дженосеа Биосайенсиз Инк. |
Вакцины против вируса простого герпеса 2 типа: композиции и способы запуска иммунного ответа
|
CA2803282C
(en)
|
2009-07-06 |
2018-05-01 |
David E. Anderson |
Methods for preparing vesicles and formulations produced therefrom
|
US9849173B2
(en)
|
2009-07-06 |
2017-12-26 |
Variation Biotechnologies Inc. |
Methods for preparing vesicles and formulations produced therefrom
|
EP2453747B1
(en)
*
|
2009-07-13 |
2017-08-30 |
Medicis Pharmaceutical Corporation |
Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
|
US20110077263A1
(en)
*
|
2009-09-29 |
2011-03-31 |
University Of Southern California |
Methods and Compositions of Toll-Like Receptor (TLR) Agonists
|
WO2011136828A1
(en)
*
|
2010-04-27 |
2011-11-03 |
The Johns Hopkins University |
Immunogenic compositions and methods for treating neoplasia
|
AU2011276223C1
(en)
|
2010-07-06 |
2016-05-12 |
Variation Biotechnologies, Inc. |
Compositions and methods for treating influenza
|
WO2012024284A1
(en)
*
|
2010-08-17 |
2012-02-23 |
3M Innovative Properties Company |
Lipidated immune response modifier compound compositions, formulations, and methods
|
US8932575B2
(en)
*
|
2010-09-21 |
2015-01-13 |
University Of Miami |
Compositions and methods for inducing migration by dendritic cells and an immune response
|
WO2012048165A2
(en)
|
2010-10-06 |
2012-04-12 |
President And Fellows Of Harvard College |
Injectable, pore-forming hydrogels for materials-based cell therapies
|
US9782474B2
(en)
|
2010-11-24 |
2017-10-10 |
Genocea Biosciences, Inc. |
Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
|
FR2969658B1
(fr)
*
|
2010-12-22 |
2014-10-17 |
Fabre Pierre Dermo Cosmetique |
Nouvelle bacterie et extraits de ladite bacterie et leur utilisation therapeutique
|
FR2969657B1
(fr)
*
|
2010-12-22 |
2014-02-07 |
Fabre Pierre Dermo Cosmetique |
Nouvelle bacterie et extraits de ladite bacterie et leur utilisation en dermatologie
|
MX359103B
(es)
|
2011-01-13 |
2018-09-14 |
Variation Biotechnologies Inc |
Composiciones y sus usos en el tratamiento de infecciones virales.
|
WO2012113413A1
(en)
*
|
2011-02-21 |
2012-08-30 |
Curevac Gmbh |
Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
|
KR102049928B1
(ko)
|
2011-08-17 |
2019-11-28 |
글로브이뮨 |
효모-muc1 면역요법 조성물 및 그 용도
|
CA2849259A1
(en)
*
|
2011-09-19 |
2013-03-28 |
The Johns Hopkins University |
Cancer immunotherapy
|
AU2012321022B2
(en)
|
2011-10-06 |
2017-03-23 |
Immunovaccine Technologies Inc. |
Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
|
JP6199878B2
(ja)
|
2011-11-23 |
2017-09-20 |
ジェノセア バイオサイエンシーズ, インコーポレイテッド |
単純ヘルペスウイルス2型に対する核酸ワクチン:免疫応答を誘発する組成物及び方法
|
CN104302323A
(zh)
|
2012-01-12 |
2015-01-21 |
变异生物技术公司 |
用于治疗病毒感染的组合物和方法
|
RU2698906C2
(ru)
|
2012-01-27 |
2019-09-02 |
Вэриэйшн Биотекнолоджиз, Инк. |
Способы и композиции для терапевтических агентов
|
CA2870309C
(en)
|
2012-04-16 |
2024-02-20 |
President And Fellows Of Harvard College |
Mesoporous silica compositions for modulating immune responses
|
KR101501583B1
(ko)
*
|
2013-03-29 |
2015-03-12 |
주식회사 차백신연구소 |
리포펩티드 및 폴리(i:c)를 포함하는 아쥬반트 및 이를 이용한 개선된 제형의 백신 조성물
|
US20160058856A1
(en)
*
|
2013-04-05 |
2016-03-03 |
Kyushu University, National University Corporation |
Anti-tumor dna vaccine
|
AU2014310934B2
(en)
|
2013-08-21 |
2019-09-12 |
CureVac SE |
Respiratory syncytial virus (RSV) vaccine
|
PL3062815T3
(pl)
|
2013-11-01 |
2019-07-31 |
Pfizer Inc. |
Wektory do ekspresji antygenów związanych z gruczołem krokowym
|
WO2015092710A1
(en)
|
2013-12-19 |
2015-06-25 |
Glaxosmithkline Biologicals, S.A. |
Contralateral co-administration of vaccines
|
US10682400B2
(en)
|
2014-04-30 |
2020-06-16 |
President And Fellows Of Harvard College |
Combination vaccine devices and methods of killing cancer cells
|
WO2016123573A1
(en)
|
2015-01-30 |
2016-08-04 |
President And Fellows Of Harvard College |
Peritumoral and intratumoral materials for cancer therapy
|
US11150242B2
(en)
|
2015-04-10 |
2021-10-19 |
President And Fellows Of Harvard College |
Immune cell trapping devices and methods for making and using the same
|
JP6534146B2
(ja)
*
|
2015-06-10 |
2019-06-26 |
国立大学法人 東京大学 |
ワクチン用アジュバント、ワクチン、及び免疫誘導方法
|
CN105031646A
(zh)
*
|
2015-07-16 |
2015-11-11 |
一达国际生物科技(北京)有限公司 |
抗肿瘤疫苗佐剂、其制备方法和编码核酸以及抗肿瘤疫苗组合物
|
WO2017024084A1
(en)
|
2015-08-03 |
2017-02-09 |
University Of Washington |
Immunogenic compositions, antigen screening methods, and methods of generating immune responses
|
CN115531609A
(zh)
|
2016-02-06 |
2022-12-30 |
哈佛学院校长同事会 |
重塑造血巢以重建免疫
|
CN115305229A
(zh)
|
2016-07-13 |
2022-11-08 |
哈佛学院院长等 |
抗原呈递细胞模拟支架及其制备和使用方法
|
JP2019537555A
(ja)
|
2016-09-28 |
2019-12-26 |
ジェノセア バイオサイエンシーズ, インコーポレイテッド |
ヘルペスを処置するための方法および組成物
|
WO2021231971A1
(en)
*
|
2020-05-14 |
2021-11-18 |
Ascendo Biotechnology, Inc. |
Selective targeting of the treml1/md2 interaction by small peptide or protein and its use for vaccine adjuvants
|
CN114377122B
(zh)
*
|
2022-01-18 |
2023-04-07 |
四川大学 |
一种基于四面体框架核酸的复合佐剂、mRNA疫苗及其制备方法和用途
|